

## Invitation to the presentation of ALK's annual report 2024 on Wednesday, 19 February 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025.

Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK's management will comment on the results and outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.

### Live audio webcast

The meeting will be audio webcasted live and be available for replay on [ALK's website](#).

### Conference call

If you wish to participate via telephone, please register for the conference call by using this link: [Registration - ALK FY 2024 - teleconference](#) and follow the instructions. You will receive an email from [diamondpass@choruscall.com](mailto:diamondpass@choruscall.com) with dial-in details, including a passcode and a pin code. Please make sure to whitelist [diamondpass@choruscall.com](mailto:diamondpass@choruscall.com) and/or check your spam filter. We advise you to register on the day before the call at the latest.

### Presentation

The presentation will be available on [ALK's website](#) shortly before the meeting starts.

## ALK-Abelló A/S

### For further information please contact:

*Investor Relations:* Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

*Media:* Maiken Riise Andersen, tel. +45 5054 1434

### About ALK

*ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at [www.alk.net](http://www.alk.net).*